Halda Partners with VantAI in USD 1b RIPTAC Drug Discovery Deal

Halda Therapeutics, founded by PROTAC pioneer Craig Crews, has entered a strategic collaboration worth over USD 1 billion with generative AI company VantAI to accelerate development of next-generation Regulated Induced Proximity TArgeting Chimeras therapeutics. The partnership combines Halda's novel hold-and-kill RIPTAC platform with VantAI's Neo-1 foundation model and NeoLink high-throughput structural proteomics platform to identify target-effector protein pairs for cancer and immune disorders. Halda's lead oral RIPTAC candidate HLD-0915/H001, targeting androgen receptor in prostate cancer, is currently in Phase I/II trials with Fast Track designation in its US homeland.

The RIPTAC technology creates heterobifunctional molecules that selectively bind disease-specific proteins and essential cellular proteins, forming inactive complexes that trigger tumour cell death. Halda has raised USD 202 million since its founding to advance this approach, with preclinical data published in Cell Chemical Biology demonstrating selective cytotoxicity in prostate cancer models. The VantAI collaboration will expand Halda's pipeline beyond HLD-0915, including programs for breast cancer and other malignancies.

According to PharmCube's NextBiopharm® database, Halda's pipeline includes four additional RIPTAC candidates in pre-clinical stage. Click here to request a free trial for NextBiopharm®.

Daily News
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis
2026-07-27
Shanghai Biopharma Fund II Closes First Tranche at RMB 1.5bn
2026-07-27
Novo Initiates Phase III Oral GLP-1R/AMYR Agonist in Obesity
2026-07-24
Roche Posts H1'26 Revenue of USD 38.4bn with Metabolic Pipeline Acceleration
2026-07-24
Byterna Raises Pre-Series A for In Vivo circmRNA CAR-T, Cancer Vaccines
2026-07-23
Latest Report
2026 TOP-25 Drug Targets
Details